Seer (NASDAQ:SEER) Director Sells $23,238.80 in Stock

Seer, Inc. (NASDAQ:SEER) Director Dipchand Nishar sold 10,660 shares of the stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $2.18, for a total transaction of $23,238.80. Following the sale, the director owned 59,044 shares of the company’s stock, valued at $128,715.92. This trade represents a 15.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Seer Stock Performance

SEER traded down $0.03 during trading on Friday, hitting $2.17. The stock had a trading volume of 300,631 shares, compared to its average volume of 602,424. The firm has a market capitalization of $119.31 million, a P/E ratio of -1.75 and a beta of 1.59. Seer, Inc. has a twelve month low of $1.55 and a twelve month high of $2.41. The company’s 50-day moving average price is $1.80 and its 200 day moving average price is $1.84.

Seer (NASDAQ:SEER) last issued its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share for the quarter, meeting the consensus estimate of ($0.30). The business had revenue of $2.79 million for the quarter, compared to the consensus estimate of $3.60 million. Seer had a negative net margin of 464.78% and a negative return on equity of 26.58%.

Analyst Ratings Changes

Several research analysts recently issued reports on SEER shares. Canaccord Genuity Group assumed coverage on Seer in a research report on Monday, May 4th. They set a “buy” rating and a $4.00 price objective for the company. TD Cowen upgraded Seer to a “strong-buy” rating in a report on Monday, April 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Seer has a consensus rating of “Buy” and an average price target of $4.00.

Institutional Investors Weigh In On Seer

A number of institutional investors have recently modified their holdings of SEER. Occudo Quantitative Strategies LP bought a new position in shares of Seer during the second quarter worth about $25,000. Marshall Wace LLP bought a new stake in Seer in the fourth quarter valued at about $85,000. Quadrature Capital Ltd acquired a new stake in Seer during the fourth quarter valued at approximately $101,000. Barclays PLC raised its stake in Seer by 685.0% during the fourth quarter. Barclays PLC now owns 60,717 shares of the company’s stock valued at $111,000 after buying an additional 52,982 shares in the last quarter. Finally, Marquette Asset Management LLC bought a new position in Seer during the 2nd quarter worth approximately $103,000. Institutional investors and hedge funds own 75.20% of the company’s stock.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.